Key Takeaways

BPC-157 has extensive animal literature and a small, fragmented human record. No adequately powered trial supports injecting it for tendon, muscle, or joint injuries, while product identity, immune effects, and long-term safety remain unresolved.

The FDA identified five small human BPC-157 studies. Two short rectal studies were randomized and placebo-controlled but exist only as meeting abstracts; the other reports were uncontrolled or extremely small. [1]
A 2025 musculoskeletal review screened 544 records and included 36 studies, of which 35 were preclinical and one was a small retrospective knee report. Its search ended in June 2024 and did not cover every proposed medical use. [2]
The July 2026 advisory vote was non-binding. BPC-157 remained absent from the federal 503A bulk-drug list when this brief was reviewed, and FDA staff recommended against listing it. [3] [4] [1]
TB-500 is a seven-amino-acid fragment associated with thymosin beta-4, not the full 43-amino-acid molecule. FDA reviewers found no human exposure or clinical-study data for TB-500 itself. [5] [6]
Testing of three semaglutide vials from online sellers found serious purity, content, and endotoxin problems in all three. The sample demonstrates that failures can occur but does not measure their prevalence or establish the quality of BPC-157 products. [7]

What is stable

BPC-157 is not an FDA-approved drug, has no recognized USP or NF monograph, and was not on the current 503A bulk-drug list at the August 2026 review date. [1] [4]
Human BPC-157 research is small, short, and not designed to establish long-term safety or clinical benefit for musculoskeletal treatment administered by injection. [1] [2]
The FDA's 40-amino-acid threshold is a regulatory definition of protein, not a rule that automatically assigns compounding status or one exclusivity period to every peptide or protein. [8]

What remains uncertain

Whether BPC-157 improves recovery from tendon, muscle, ligament, or joint injury in people remains unsettled. Animal models and uncontrolled reports cannot provide the answer. [1] [2]
Long-term toxicity, immune reactions, human pharmacokinetics, and cancer risk are unknown. Angiogenic activity supplies a mechanistic concern, but no human evidence establishes a cancer effect. [1]
The FDA may accept or reject its advisory committee's recommendation through later action. The July 2026 vote did not settle the question. [3]

Common questions

Is BPC-157 safe?

Available human reports are too small and short to establish safety. The FDA found no adequate long-term, carcinogenicity, reproductive, or formal immunogenicity assessment and noted unresolved questions about product identity and impurities. [1]

Has BPC-157 been tested in randomized human trials?

Yes, but only in a narrow and incomplete sense. FDA reviewers identified two short randomized, placebo-controlled rectal studies reported as meeting abstracts. Neither supplies fully published evidence for musculoskeletal treatment administered by injection. The remaining human reports were uncontrolled, retrospective, or involved only two participants. [1]

Can a U.S. pharmacy legally compound BPC-157?

BPC-157 was absent from the 503A bulk-drug list at the August 2026 review date, is not a component of an FDA-approved drug, and has no USP or NF monograph. The advisory vote did not amend federal rules. State requirements and later federal action can also affect a particular case. [1] [4] [3]

What did the July 2026 FDA advisory vote change?

The committee recommended allowing compounding of BPC-157 by an 8-6 vote with one abstention. Its advice is non-binding and did not itself change the 503A list or approve a drug. [3] [4]

Are TB-500 and thymosin beta-4 the same?

No. FDA describes TB-500 as a synthetic seven-amino-acid fragment related to the full 43-amino-acid thymosin beta-4 molecule. Human trial results for full thymosin beta-4 cannot be assigned to the shorter fragment. FDA reviewers found no human studies of TB-500 itself. [5] [6]

What do online-product purity tests establish?

One study bought and tested three semaglutide vials. Purity ranged from 7.7% to 14.37% against 99% label claims. Each vial contained excess semaglutide and detectable endotoxin. The study did not test BPC-157 or estimate how often such failures occur across sellers. [7]

Are BPC-157 and TB-500 prohibited in sport?

Yes. The 2026 WADA list prohibits BPC-157 as a non-approved substance and names TB-500 among growth-factor modulators. A prescription alone does not replace the anti-doping therapeutic-use-exemption process. [9]

Does a ClinicalTrials.gov entry prove that a peptide trial is real?

No. The registry displays information submitted by sponsors and investigators. In August 2026, peptide records marked as recruiting included TB-500 and tesamorelin entries whose own text called them fictional or mock, while the BPC-157 entry did not carry that wording. A listing needs verification beyond its recruitment label. [10] [11] [12]

BPC-157, Peptide Therapies, and Product Risk